NCT04684498

Open-label Study of Neuraminidase Inhibitor Treatment in STEMI Patients

An Open-label Study to Evaluate the Efficacy of Neuraminidase Inhibitor Treatment in ST-Elevation Myocardial Infarction (STEMI) Patients

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 382 (estimated)
• Sponsor: Tongji Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Neuraminidase-1 can cause the removal of terminal sialic acid residues from the cell surface or serum sialyloconjugates. The level of Neu5Ac was positively related to the activity of neuraminidase-1. Elevation of Neu5Ac was observed in myocardial ischemia animal model, as well as patients with coronary artery disease. It is interesting to note that Neu5Ac and its regulatory enzyme neuraminidase-1 seem to play a key role in triggering myocardial ischemic injury. Oseltamivir, a structural mimic of sialic acid, was widely used as anti-influenza drug. It suppressed neuraminidase-1 activity in the heart. Targeting neuraminidase-1 may represent a new therapeutic intervention for coronary artery disease. This project seeks to identify whether neuraminidase inhibitor (Oseltamivir) treatment could decrease the myocardial infarct size in STEMI patients and improve clinical outcomes.

Conditions

• ST Elevation Myocardial Infarction
• STEMI

Interventions

Type	Name	Description
DRUG	Oseltamivir phosphate capsules	Treatment group vs. Control group

Timeline

• Start date: 2020-03-01
• Primary completion: 2023-06-30
• Completion: 2024-03-31
• First posted: 2020-12-24
• Last updated: 2020-12-24

Locations

1 site across 1 country: China